scholarly journals Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

2017 ◽  
Vol 28 (5) ◽  
Author(s):  
Xinxin Zhu ◽  
Jinghe Lang
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Effect ◽  
Synergistic Antitumor Effect ◽  
Combined Application ◽  
Programmed Death ◽  
Programmed Death 1

scholarly journals Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients

2020 ◽  
Vol Volume 12 ◽  
pp. 9691-9709
Author(s):  
Anna Pawłowska ◽  
Dorota Suszczyk ◽  
Rafal Tarkowski ◽  
Roman Paduch ◽  
Jan Kotarski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Programmed Death ◽  
Programmed Death 1

Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor

2020 ◽  
Vol 157 (1) ◽  
pp. 222-233 ◽  
Author(s):  
Chunyan Xue ◽  
Yun Xu ◽  
Wenfeng Ye ◽  
Quanqin Xie ◽  
Hongyan Gao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Effect ◽  
Parp Inhibitor ◽  
Synergistic Antitumor Effect

scholarly journals Immune checkpoint inhibitors in ovarian cancer: where do we stand?

2021 ◽  
Vol 13 ◽  
pp. 175883592110398
Author(s):  
Alexandra Leary ◽  
David Tan ◽  
Jonathan Ledermann
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Studies ◽  
Immune Cell ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
Parp Inhibitors ◽  
Early Results ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Immune Oncology

Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.

PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer

2018 ◽  
Author(s):  
Scott Moerdler ◽  
Xingxing Zang
Keyword(s):  
Ovarian Cancer ◽  
T Cell Activation ◽  
Cell Activation ◽  
Immune Escape ◽  
Tumor Infiltrating Lymphocytes ◽  
Immunoglobulin Superfamily ◽  
Combination Therapies ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Infiltrating Lymphocytes

Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be responsive to anti-PD-1 and anti-PD-L1 therapies, though immunocheckpoint inhibitors are not enough. Current research is evaluating combination therapies to improve response rates.

Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer

2014 ◽  
Author(s):  
Kshipra M. Gharpure ◽  
Kevin S. Chu ◽  
Charles Bowerman ◽  
Takahito Miyake ◽  
Sunila Pradeep ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Effect ◽  
Synergistic Antitumor Effect
Sign in / Sign up

Export Citation Format

Share Document